Apertura Gene Therapy is a biotechnology company focused on pioneering next-generation AAV gene therapies through innovative capsid and payload engineering. The company's core mission is to open new opportunities for treating debilitating diseases with limited patient options. Apertura designs AAV capsids, regulatory elements, and payloads to overcome existing limitations in gene delivery and expression, aiming to bring the future of gene therapy into focus.
Apertura Gene Therapy has assembled a world-class team of experts in vector engineering, gene regulation, machine learning, and the treatment of rare diseases. This collaborative effort has enabled the company to build a robust pipeline of advanced gene therapies. Their innovative approach and cutting-edge technology have positioned them as leaders in the field, making significant strides in addressing unmet medical needs.
